PL376219A1 - Stabilizowane cząstki polipeptydu w stanie stałym - Google Patents

Stabilizowane cząstki polipeptydu w stanie stałym

Info

Publication number
PL376219A1
PL376219A1 PL03376219A PL37621903A PL376219A1 PL 376219 A1 PL376219 A1 PL 376219A1 PL 03376219 A PL03376219 A PL 03376219A PL 37621903 A PL37621903 A PL 37621903A PL 376219 A1 PL376219 A1 PL 376219A1
Authority
PL
Poland
Prior art keywords
stabilized
solid
polypeptide particles
state polypeptide
state
Prior art date
Application number
PL03376219A
Other languages
English (en)
Inventor
Johanna Bentz
Ling-Ling Kang
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of PL376219A1 publication Critical patent/PL376219A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL03376219A 2002-10-29 2003-10-28 Stabilizowane cząstki polipeptydu w stanie stałym PL376219A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42228902P 2002-10-29 2002-10-29

Publications (1)

Publication Number Publication Date
PL376219A1 true PL376219A1 (pl) 2005-12-27

Family

ID=32230336

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376219A PL376219A1 (pl) 2002-10-29 2003-10-28 Stabilizowane cząstki polipeptydu w stanie stałym

Country Status (20)

Country Link
US (1) US20060198894A1 (pl)
EP (1) EP1562626B1 (pl)
JP (1) JP2006504772A (pl)
KR (1) KR20050083841A (pl)
CN (1) CN1708314A (pl)
AU (1) AU2003285075B2 (pl)
BR (1) BR0315782A (pl)
CA (1) CA2502378A1 (pl)
DE (1) DE60317822D1 (pl)
EC (1) ECSP055822A (pl)
IL (1) IL168106A0 (pl)
MX (1) MXPA05004593A (pl)
MY (1) MY138608A (pl)
NO (1) NO20052422L (pl)
NZ (2) NZ562480A (pl)
PL (1) PL376219A1 (pl)
RU (1) RU2329823C2 (pl)
TW (1) TW200505497A (pl)
WO (1) WO2004039392A2 (pl)
ZA (1) ZA200504311B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
US20190330295A1 (en) * 2005-05-04 2019-10-31 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP4847775B2 (ja) * 2006-03-29 2011-12-28 シーシーアイ株式会社 安定なポリオール脱水素酵素組成物
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPH02218618A (ja) * 1989-02-21 1990-08-31 Green Cross Corp:The トロンビン粉末製剤
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
ES2087323T3 (es) * 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
JP3356816B2 (ja) * 1992-03-24 2002-12-16 セイコーインスツルメンツ株式会社 半導体光電気変換装置
JPH083056A (ja) * 1994-06-17 1996-01-09 Nippon Kayaku Co Ltd 末梢神経障害の軽減剤
JPH08131171A (ja) * 1994-11-11 1996-05-28 Asahi Chem Ind Co Ltd 逆転写酵素の安定化組成物
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
PT1238659E (pt) * 1996-02-02 2005-01-31 Alza Corp Libertacao sustentada de um agente activo utilizando um sistema implantavel
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0959873B1 (en) * 1996-12-20 2006-03-01 ALZA Corporation Gel composition and methods
ID22933A (id) * 1997-04-28 1999-12-16 Lilly Co Eli Fomulasi protien c terakivasi
JP4156688B2 (ja) * 1997-07-22 2008-09-24 アルフレッサファーマ株式会社 安定なヘモグロビン含有組成物
PT1041975E (pt) * 1997-12-22 2003-01-31 Alza Corp Membranas de controlo de taxa para dispositivos de fornecimento controlado de drogas
ES2378675T3 (es) * 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Sistema de suministro de un agente beneficioso con una membrana obturadora
DE60034445T2 (de) * 1999-05-31 2008-01-03 Mitsubishi Chemical Corp. Gefriergetrocknete hgf-präparationen
AU2003219787A1 (en) * 2002-02-14 2003-09-04 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII

Also Published As

Publication number Publication date
MXPA05004593A (es) 2005-07-26
RU2329823C2 (ru) 2008-07-27
US20060198894A1 (en) 2006-09-07
JP2006504772A (ja) 2006-02-09
NZ539811A (en) 2008-08-29
MY138608A (en) 2009-07-31
AU2003285075B2 (en) 2009-10-29
RU2005116250A (ru) 2006-01-20
DE60317822D1 (de) 2008-01-10
NO20052422L (no) 2005-07-20
AU2003285075A1 (en) 2004-05-25
NO20052422D0 (no) 2005-05-19
TW200505497A (en) 2005-02-16
ZA200504311B (en) 2006-07-26
EP1562626A2 (en) 2005-08-17
WO2004039392A3 (en) 2004-09-30
KR20050083841A (ko) 2005-08-26
BR0315782A (pt) 2005-09-20
IL168106A0 (en) 2009-02-11
WO2004039392A2 (en) 2004-05-13
CA2502378A1 (en) 2004-05-13
NZ562480A (en) 2009-08-28
CN1708314A (zh) 2005-12-14
EP1562626B1 (en) 2007-11-28
ECSP055822A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
IL168106A0 (en) Stabilized, solid-state polypeptide particles
AU2003243436A8 (en) Reconstituted polypeptides
EG25378A (en) Powder inhalator.
AU2003301769A8 (en) Stabilized semiconductor nanocrystals
AU2003293294A8 (en) Uv-stabilised particles
IL165609A0 (en) Pegylated factor VII glycoforms
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
HK1065171A1 (en) Connecting modul
AU2003225901A8 (en) Stabilized inorganic particles
EP1559433A4 (en) STABILIZED COMPOSITION
ZA200305329B (en) Heatselable filter material.
IL164157A0 (en) Granulated wettabile powder
ZA200409971B (en) Powder formulations.
EP1614695A4 (en) POLYPEPTIDE
GB0218977D0 (en) Polypeptide
GB0223193D0 (en) Polypeptide
GB0202275D0 (en) Peptide
GB0208925D0 (en) Polypeptide
GB0210746D0 (en) Peptide
GB2395068B (en) Solid state imager
EP1477559A4 (en) NEW POLYPEPTIDE
GB0219720D0 (en) Polypeptide
GB0222181D0 (en) Polypeptide
GB0202221D0 (en) Novel polypeptide
GB0224933D0 (en) Sintering components

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)